Analysts predict that Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) will report earnings of ($0.31) per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Aurinia Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($0.33). Aurinia Pharmaceuticals reported earnings of ($0.29) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 6.9%. The firm is expected to announce its next earnings report on Thursday, March 4th.
According to Zacks, analysts expect that Aurinia Pharmaceuticals will report full-year earnings of ($0.91) per share for the current financial year, with EPS estimates ranging from ($1.03) to ($0.60). For the next financial year, analysts forecast that the company will report earnings of ($0.87) per share, with EPS estimates ranging from ($1.26) to ($0.07). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Sunday, November 15th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.05). Aurinia Pharmaceuticals had a negative return on equity of 36.98% and a negative net margin of 173,992.23%. The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.06 million.
A number of equities analysts have recently issued reports on AUPH shares. Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, December 22nd. Bloom Burton lowered shares of Aurinia Pharmaceuticals from a “buy” rating to an “accumulate” rating in a research report on Tuesday, November 3rd. Cantor Fitzgerald reduced their target price on shares of Aurinia Pharmaceuticals from $30.00 to $26.00 in a research report on Thursday, November 12th. Oppenheimer restated a “buy” rating and issued a $20.00 price objective on shares of Aurinia Pharmaceuticals in a report on Thursday, December 17th. Finally, ValuEngine upgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, December 17th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $22.75.
Large investors have recently modified their holdings of the business. Advisory Alpha LLC bought a new stake in Aurinia Pharmaceuticals in the third quarter valued at approximately $31,000. Captrust Financial Advisors bought a new stake in Aurinia Pharmaceuticals in the second quarter valued at approximately $35,000. Skandinaviska Enskilda Banken AB publ bought a new stake in Aurinia Pharmaceuticals in the second quarter valued at approximately $75,000. Exane Derivatives increased its position in shares of Aurinia Pharmaceuticals by 50.0% during the third quarter. Exane Derivatives now owns 5,100 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 1,700 shares in the last quarter. Finally, tru Independence LLC increased its position in shares of Aurinia Pharmaceuticals by 9.9% during the second quarter. tru Independence LLC now owns 8,900 shares of the biotechnology company’s stock worth $145,000 after acquiring an additional 800 shares in the last quarter. 46.48% of the stock is owned by hedge funds and other institutional investors.
Shares of AUPH stock opened at $13.66 on Tuesday. Aurinia Pharmaceuticals has a 1 year low of $9.83 and a 1 year high of $21.81. The firm’s 50 day moving average is $14.11 and its 200-day moving average is $14.67. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of -9.29 and a beta of 0.92.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Further Reading: NASDAQ Stock Market Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.